Palifermin

Generic Name: Palifermin
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20020402Mucositis associated with radiation therapy and concurrent chemotherapy in subjects with HNC3A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Cancer Receiving Radiotherapy with Concurrent Chemotherapy (RT/CT)
20030185Dysphagia caused by radiation therapy (RT) with concurrent chemotherapy2A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
20040124Oral Mucositis associated with adjuvant radiation and concurrent chemotherapy in postoperative HNC setting1/2A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy with Concurrent Chemotherapy
20050100Oral mucositis induced by high-dose chemotherapy in subjects with NHL or MM4An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects with Non -Hodgkins Lymphoma (NHL) or Multiple Myeloma (MM) Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation